Dianna Magliano

Lab Head/ Epidmiologist

Baker Heart and Diabetes Institute

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dianna Magliano is a Lab Head and Epidemiologist at the Baker Heart and Diabetes Institute in Australia. Her research primarily focuses on the epidemiology of diabetes and its complications, particularly in relation to cognitive decline, cardiovascular disease, and the global prevalence of prediabetes. Recent publications include studies on the impact of diabetes remission strategies and emerging insights into adult-onset type 1 diabetes.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (16)

Julian Sacre

Baker Heart and Diabetes Institute

AUSTRALIA

Dianna Magliano

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

Global and Regional Prediabetes Prevalence: Updates for 2024 and Projections for 2050

Trends in the prevalence of cardiovascular disease, defined as ECG abnormalities and/or self-reported events, in Mauritius between 1987 and 2021: analysis of data from seven large population-based surveys

Associations of glycaemia‐related risk factors with dementia and cognitive decline in individuals with type 2 diabetes: A systematic review and meta‐analysis

Impact of eligibility for diabetes remission on response to intensive lifestyle intervention in overweight and obese people with type 2 diabetes: The Look AHEAD trial

Variation in type 2 diabetes prevalence across different populations: the key drivers

The epidemiology of type 1 diabetes mellitus in older adults

Adult-onset type 1 diabetes: new insights but still much to learn

SGLT‐2 Inhibitor Use and Cause‐Specific Hospitalization Rates: An Outcome‐Wide Study to Identify Novel Associations of SGLT‐2 Inhibitors

Imputation of plasma lipid species to facilitate integration of lipidomic datasets

Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022–2031

Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis

The T1D Index: Implications of Initial Results, Data Limitations, and Future Development

Global Prevalence of Prediabetes

Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century

Youth-onset type 2 diabetes mellitus: an urgent challenge

The burden and risks of emerging complications of diabetes mellitus

Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy

Collaborators (16)

Julian Sacre

Jonathan Shaw

Amelia Wallace

Justin B. Echouffo‐Tcheugui

Kanika Mehta

Kevan Polkinghorne

Clara Marquina

Jean Yang

trevor orchard

George (Shao Qian) Tan

Peter A. Lazzarini

Edward Boyko

Stefan Söderberg

jessica harding

Zanfina Ademi

Danny Liew

Make your next move.